HOME NEWS EARNINGS RESULTS PICKS STRATEGY BLOG CONTACT SUBSCRIBE LOGIN SUBSCRIBE JOIN FREE
LOADING—
Price Investing Group
← Back to Research Watchlist
BCAX
Bicara Therapeutics Inc
Healthcare Biotechnology · Massachusetts, USA · Reports in usd
—
Market Cap: $1.15B
Market Cap
$1.15B
Enterprise Val
$653.7M
P/E Ratio
-6.20
P/B Ratio
2.45
Trailing PEG (1Y)
-0.10
As Of
Oct 8, 2026

Overview & Key Metrics

Reporting period: Jun 30, 2026 · Q2 2026
Book Value$468.8M
Return on Equity-41.49%
Return on Assets-38.59%
Current Ratio11.59
Debt/Equity0.00
LT Debt/Equity0.00
Revenue Per Share0.00

Income Statement

Jun 30, 2026
Revenue$0.00
Cost of Revenue$0.00
Gross Profit$0.00
R&D$45.8M
SG&A$14.2M
Operating Expenses$60.0M
Operating Income-$60.0M
Interest Expense$0.00
Tax Expense$61.0K
Net Income-$55.4M
EPS (Basic)$-0.82
EPS (Diluted)$-0.82
EBIT-$55.4M
EBITDA-$55.1M
Consolidated Income-$55.4M
Non-Controlling Interests$0.00

Balance Sheet

Jun 30, 2026
Cash & Equivalents$96.6M
Accounts Receivable$0.00
Inventory$0.00
Current Assets$503.8M
LT Investments$0.00
Property, Plant & Equipment$1.5M
Intangibles$0.00
Non-Current Assets$8.4M
Total Assets$512.2M
Accounts Payable$8.5M
Current Debt$1.2M
Current Liabilities$43.5M
LT Debt$0.00
Non-Current Liabilities$0.00
Total Liabilities$43.5M
Total Debt$1.2M
Retained Earnings-$470.6M
Shareholder Equity$468.8M
Shares Outstanding65,703,866

Cash Flow Statement

Jun 30, 2026
Operating Cash Flow-$44.2M
Investing Cash Flow-$185.0M
Financing Cash Flow$2.3M
CapEx-$60.0K
Free Cash Flow-$44.3M
Depreciation & Amort.$321.0K
Stock-Based Comp$8.2M
Acquisitions / Disposals$0.00
Investment Activity-$184.9M
Debt Issued/Repaid$0.00
Equity Issued/Repaid$2.3M
Dividends Paid$0.00
Net Change in Cash-$226.9M
Data cached · Meta live · Daily live · Statements live · TTL 24h